Penfigoide de las mucosas
revisión de conceptos y consenso terapéutico intersocietario
DOI:
https://doi.org/10.70313/2718.7446.v16.nS2.365Palabras clave:
penfigoide de las membranas mucosas, penfigoide, superficie ocular, dermatología, oftalmologíaResumen
El penfigoide de las membranas mucosas es un grupo heterogéneo de enfermedades ampollares autoinmunes inflamatorias crónicas que compro- meten las mucosas y en ocasiones, la piel.
En la Guía intersocietaria de manejo de penfigoide de las membranas mucosas publicada en 2023, la Sociedad Argentina de Dermatología y la Sociedad Argentina de Superficie Ocular realizaron una re- visión bibliografía sobre los mecanismos fisiopa- tológicos de la enfermedad, las manifestaciones clínicas en las diferentes mucosas, las opciones de tratamiento sistémico y el manejo de la superficie ocular.
Descargas
Referencias
Giuli Santi C, Gripp AC, Roselino AM et al. Consensus on the treatment of autoimmune bu- llous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bu- llosa acquisita - Brazilian Society of Dermato- logy. An Bras Dermatol 2019; 94 (Sup. 1): 33-47.
Rashid H, Lamberts A, Borradori L et al. European guidelines (S3) on diagnosis and ma- nagement of mucous membrane pemphigoid, initiated by the European Academy of Derma- tology and Venereology: part I. J Eur Acad Der- matol Venereol 2021; 35: 1750-1764.
Candiz ME, Forero OL, Label M, Di Milia M, Galperín G (dirs.). Guía intersocietaria del manejo del penfigoide de las mucosas. Buenos Aires: Sociedad Argentina de Dermatología; So- ciedad Argentina de Superficie Ocular, [2023]. Disponible en: https://sad.org.ar/wp-content/ uploads/2023/04/GUIA-INTERSOC.-DE-MA- NEJO-DE-PENFIGOIDE-DE-LAS-MUCO- SAS-corregidas-por-ECOF-28032023-final.pdf.
Kels BD, Grzybowski A, Grant-Kels JM. Hu- man ocular anatomy. Clin Dermatol 2015; 33: 140-146.
Bron AJ, Tripathi RC, Tripathi BJ. Wolff ’s Anatomy of the eye and orbit. 8th ed. London: Chapman & Hall, 1997.
Tseng SC, Tsubota K. Important concepts for treating ocular surface and tears disorders. Am J Ophthalmol 1997; 124: 825-835.
Kaufman PL, Alm A (eds.). Adler Fisiología del ojo: aplicación clínica. Madrid: Elsevier Es- paña, 2003.
Inatomi T, Spurr-Michaud S, Tisdale AS, Gipson IK. Human corneal and conjunctival epithelia express MUC1 mucin. Invest Ophthal- mol Vis Sci 1995; 36: 1818-1827.
Dua HS, Azuara-Blanco A. Limbal stem cells of the corneal epithelium. Surv Ophthalmol 2000; 44: 415-425.
Du G, Patzelt S, van Beek N, Schmidt E. Mu- cous membrane pemphigoid. Autoimmun Rev 2022; 21: 103036.
Alvaro Y, Olivares L, Forero OL, Candiz ME et al. Penfigoide de las mucosas relacionado con probable enfermedad inflamatoria intestinal: a propósito de un caso. Med Cutan Iber Lat Am 2021; 49: 1-6.
Kamaguchi M, Iwata H. The diagnosis and blistering mechanisms of mucous membrane pemphigoid. Front Immunol 2019; 10: 34.
Sun S, Karsdal MA. Type XVII collagen. En: Karsdal MA, Leeming DJ, Henriksen K, Bay-Jensen AC (eds.). Biochemistry of collagens, laminins and elastin: estructure, function, and biomarkers. Amsterdam: Academic Press, 2016, cap. 17, p. 107-111.
Heppe EN, Tofern S, Schulze FS et al. Ex- perimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and re- flects clinical and immunopathological charac- teristics of the human disease. J Invest Dermatol 2017; 137: 1709-1718.
Rashid KA, Gürcan HM, Ahmed AR. Anti- gen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006; 126: 2631- 2636.
Xu HH, Werth VP, Parisi E, Sollecito TP. Mucous membrane pemphigoid. Dent Clin Nor- th Am 2013; 57: 611-630.
Olivares L. Penfigoide de las mucosas. En: Fo- rero OL, Candiz ME, Olivares L. Dermatosis am- pollares autoinmunes: haga su diagnóstico. Buenos Aires: Ediciones Journal, 2021, p. 220-223.
Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84: 527-663.
Dacosta J. Ocular cicatricial pemphigoid masquerading as chronic conjunctivitis: a case report. Clin Ophthalmol 2012; 6: 2093-2095.
Ilie MA, Caruntu C, Lupu M et al. Current and future applications of confocal laser scan- ning microscopy imaging in skin oncology. On- col Lett 2019; 17: 4102-4111.
Ilie MA, Caruntu C, Lixandru D et al. In vivo confocal laser scanning microscopy ima- ging of skin inflammation: clinical applications and research directions. Exp Ther Med 2019; 17: 1004-1011.
Duke-Elder S. System of ophthalmology. St Louis: C. V. Mosby, 1965, vol. 8, part 1, p 502.
Williams GP, Radford C, Nightingale P et al. Evaluation of early and late presentation of patients with ocular mucous membrane pem- phigoid to two major tertiary referral hospitals in the United Kingdom. Eye (Lond) 2011; 25: 1207-1218.
Mondino BJ, Linstone FA. Ocular pemphi- goid. Clin Dermatol 1987; 5: 28-35.
Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology 1981, 88: 95-100.
Elder MJ, Bernauer W, Leonard J, Dart JK. Progression of disease in ocular cicatricial pem- phigoid. Br J Ophthalmol 1996; 80: 292-296.
Brănişteanu DE, Pintilie A, Andreş LE et al. Ethiopatogenic hypotheses in lichen planus. Rev Med Chir Soc Med Nat Iasi 2016; 120: 760-767.
Tatu AL, Cristea VC. Unilateral blepharitis with fine follicular scaling. J Cutan Med Surg 2017; 21: 442.
Foster CS, Sainz de la Maza M. Ocular ci- catricial pemphigoid review. Curr Opin Allergy Clin Immunol 2004; 4: 435-439.
Amber KT, Murrell DF, Schmidt E et al. Au- toimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 2018; 54: 26-51.
Michalska-Jakubus M, Wdowiak-Filip A, Kowaleski C et al. Localized blistering eruption of the face and neck: a case study and differen- tial considerations. Clin Cosmet Investig Derma- tol 2022; 15: 271-281.
Tula M. Penfigoide de las mucosas. Derma- tol Argent 2012; 18: 16-23.
Broussard KC, Leung TG, Moradi A et al. Autoimmune bullous diseases with skin and eye involvement: cicatricial pemphigoid, pemphi- gus vulgaris, and pemphigus paraneoplastica. Clin Dermatol 2016; 34: 205-213.
Forero OL, Candiz ME, Olivares L. Derma- tosis ampollares autoinmunes: haga su diagnós- tico. Buenos Aires: Ediciones Journal, 2021, p. 1-52.
Schmidt E, Rashid H, Marzano AV et al. European guidelines (S3) on diagnosis and ma- nagement of mucous membrane pemphigoid, initiated by the European Academy of Derma- tology and Venereology: part II. J Eur Acad Der- matol Venereol 2021; 35: 1926-1948.
Murrell DF, Marinovic B, Caux F et al. De- finitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol 2015; 72: 168-174.
Hegarty AM, Ormond M, Sweeney M, Ho- dgson T. Dapsone efficacy and adverse events in the management of mucous membrane pem- phigoid. Eur J Dermatol 2010; 20: 223-224.
Mannis MJ; Holland EJ (eds.). Cornea. 5th ed. London: Elsevier. 2022, 2 v.
Ogawa Y, Okamoto S, Mori T et al. Autolo- gous serum eye drops for the treatment of seve- re dry eye in patients with chronic graft-versus- host disease. Bone Marrow Transplant 2003; 31: 579-583.
Ali T, Perez VL. Autologous serum tears in autoimmune diseases: is it bad blood? Personal communication, 2015.
Gibbons A, Jhonson TE, Wester ST et al. Management of patients with confirmed and presumed mucous membrane pemphigoid un- dergoing entropion repair. Am J Ophthalmol 2015; 159: 846.e2-852.e2.
Holland EJ, Olsen TW, Ketcham JM et al. Topical cyclosporin A in the treatment of an- terior segment inflammatory disease. Cornea 1993; 12: 413-419.
Lee YJ, Kim SW, Seo KY. Application for tacrolimus ointment in treating refractory in- flammatory ocular surface diseases. Am J Oph- thalmol 155: 804-813.
Branisteanu DC, Stoleriu G, Branisteanu DE et al. Ocular cicatricial pemphigoid (review). Exp Ther Med 2020; 20: 3379-3382.
Singh S, Donthineni PR, Shanbhag SS et al. Drug induced cicatrizing conjunctivitis: a case series with review of etiopathogenesis, diagno- sis and management. Ocul Surf 2022; 24: 83-92.
Gottsch JD, Li Q, Ashraf F et al. Cytokine-in- duced calgranulin C expression in keratocytes. Clin Immunol 1999; 91: 34-40.
Priyadarshini K, Sharma N, Kaur M, Titiyal JS. Cataract surgery in ocular surface disease. Indian J Ophthalmol 2023; 71: 1167-1175.
He Y, Quan Z, Zhang R et al. Perioperative management and long-term outcomes in ocular ci- catricial pemphigoid patients undergoing cataract surgery. Oxid Med Cell Longev 2022; 2022: 2496649.
Badoza D, Rodríguez EC, Aguilar A, Zárate J. Cirugía de catarata en pacientes con penfigoide ocular cicatricial. Oftalmol Clin Exp 2019; 12: 7-14.
Di Milia MB, Dickson C (dirs.). Guías de ma- nejo de los pénfigos. Buenos Aires: Sociedad Argen- tina de Dermatología, 2020. Disponible en: https:// sad.org.ar/wp-content/uploads/2020/06/Guias-de- manejo-de-penfigo-2020.-.pdf.
Onghanseng N, Ng SM, Halim MS, Nguyen QD. Oral antibiotics for chronic blepharitis. Co- chrane Database Syst Rev 2021; 6: CD013697.
Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in der- matology. Australas J Dermatol 2014; 55: 111-118.
Miyamoto D, Giuli Santi C, Aoki V, Maruta C. Bullous pemphigoid. An Bras Dermatol 2019; 94:133-146.
Navarro-Triviño FJ, Pérez-López I, Ruiz-Villa- verde R. Doxiciclina, ¿antibiótico o antiinflamato- rio?: usos más frecuentes en dermatología. Actas Dermosifiliogr 2020; 111 (7): 561-566.
Carrozzo M, Arduino P, Bertolusso G et al. Sys- temic minocycline as a therapeutic option in pre- dominantly oral mucous membrane pemphigoid: a cautionary report. Int J Oral Maxillofac Surg 2009; 38: 1071-1076.
Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in der- matology. Australas J Dermatol 2014; 55: 111-118.
Borradori L, Van Beek N, Feliciani C et al. Up- dated S2 K guidelines for the management of bu- llous pemphigoid initiated by the European Aca- demy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36: 1689-1704.
Delaumenie S, Assikar S, Prudhomme R et al. Methotrexate is safe and efficient as long-term treatment for bullous pemphigoid. Eur J Dermatol 2019; 29: 217-218.
Wojtczak M, Nolbrzak A, Woźniacka A, Że- browska A. Can methotrexate be employed as monotherapy for bullous pemphigoid?: analysis of efficiency and tolerance of methotrexate treatment in patients with bullous pemphigoid. J Clin Med 2023; 12: 1638.
Juri MC, Fernández Romero DS, Devoto MH et al. Tratamiento sistémico del penfigoide cicatri- zal ocular. Medicina (B Aires) 2012, 72: 103-108.
Nottage JM, Hammersmith KM, Murchison AP et al. Treatment of mucous membrane pem- phigoid with mycophenolate mofetil. Cornea 2013; 32: 810-815.
Doycheva D, Deuter C, Blumenstock G et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm 2011; 19: 431-438.
Staines K, Hampton PJ. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolo- ne: a case series. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: e49-e56.
Orvis AK, Wesson SK, Breza TS Jr. et al. Myco- phenolate mofetil in dermatology. J Am Acad Der- matol 2009; 60: 183-199.
Mazzaroni S, Forero OL, Candiz ME et al. La importancia de la solicitud de tiopurina metiltrans- ferasa para el inicio de la azatioprina: nuestra expe- riencia. Dermatol Argent 2018; 24: 199-201.
Saw VPJ, Dart JKG, Rauz S et al. Immunosu- ppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmo- logy 2008; 115: 253-261.
Forero OL, Candiz ME (dirs.). Guías de mane- jo de penfigoide ampollar. Buenos Aires: Sociedad Argentina de Dermatología, 2021. Disponible en: https://sad.org.ar/wp-content/uploads/2021/09/ Guias-de-manejo-de-PA.pdf
Kremer N, Snast I, Cohen ES et al. Rituximab and omalizumab for the treatment of bullous pem- phigoid: a systematic review of the literature. Am J Clin Dermatol 2019; 20: 209-216.
Kaegi C, Wuest B, Schreiner J et al. Systema- tic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Im- munol 2019; 10: 1990.
Maley A, Warren M, Haberman I et al. Ritu- ximab combined with conventional therapy ver- sus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 2016; 74: 835-840.
Thomas RM, Colon A, Motaparthi K. Rituxi- mab in autoimmune pemphigoid diseases: indications, optimized regimens, and practice gaps. Clin Dermatol 2020; 38: 384-396.
Bevans SL, Parker J, Ivey JM et al. Rituximab as an adjuvant rescue treatment for ocular cicatrizal pemphigoid. Cornea 2021; 40: 1440-1444.
Dastmalchi DA, Moslemkhani S, Bayat M et al. The efficacy of rituximab in patients with mucous membrane pemphigoid. J Dermatolog Treat 2022; 33: 1084-1090.
Lamberts A, Euverman HI, Terra JB et al. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol 201; 9: 248.
Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol 2013; 69: 310-311.
Farooq MM, Miloslavsky EM, Konikov N, Ah- med AR. Use of rituximab in the treatment of mu- cous membrane pemphigoid: an analytic review. Autoimmun Rev 2022; 21: 103119.
Rashid H, Meijer JM, Bolling MC, Horváth B. Clinical response to rituximab and improvement in quality of life in patients with bullous pemphigoid and mucous membrane pemphigoid. Br J Dermatol 2022; 186: 721-723.
Hoffmann JHO, Enk AH. High-dose intrave- nous immunoglobulin in skin autoimmune disea- se. Front Immunol 2019; 10: 1090.
Ahmed AR, Colón JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001; 137: 1181-1189.
Sami N, Bhol KC, Ahmed RA. Intravenous im- munoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pem- phigoid. Clin Immunol 2002; 102: 59-67.
Letko E, Miserocchi E, Daoud YJ et al. A nonran- domized comparison of the clinical outcome of ocu- lar involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional im- munosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004; 111: 303-310.
Arumugham VB, Rayi A. Intravenous immu- noglobulin (IVIG). 2023 Jul 3. En: StatPearls [re- curso web]. Treasure Island, Estados Unidos: Sta- tPearls Publishing, 3 jul. 2023.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Consejo Argentino de Oftalmología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Con esta licencia no se permite un uso comercial de la obra original, ni la generación de obras derivadas. Las licencias Creative Commons permiten a los autores compartir y liberar sus obras en forma legal y segura.
